Understanding the genetic basis of Glanzmann thrombasthenia: Implications for treatment

Expert Review of Hematology

Volumn 5, Issue 5, 2012, Pages 487-503

  Nurden, Alan T ^a   Pillois, Xavier ^a,b   Nurden, Paquita ^a  

^a Ctr Geriatrie Ctr Hosp Univ B   (France)

^b INSERM   (France)

Author keywords

IIb 3 integrin; Glanzmann thrombasthenia; inherited bleeding syndrome; platelet aggregation; treatment

Indexed keywords

ALPHAIIBBETA3 INTEGRIN; INTEGRIN RECEPTOR; UNCLASSIFIED DRUG;

BLEEDING; GENE FUNCTION; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; GEOGRAPHIC DISTRIBUTION; GLANZMANN DISEASE; HUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; REVIEW; THROMBOCYTOPENIA;

HUMANS; INTEGRIN ALPHA2; INTEGRIN ALPHAVBETA3; INTEGRIN BETA3; MUTATION; PLATELET AGGREGATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN STRUCTURE, TERTIARY; THROMBASTHENIA;

EID: 84869193874     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.46     Document Type: Review

References (117)

1. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: The spectrum of clinical disease. Blood 75(7), 1383-1395 (1990). phenotype with reference to a large number of case reports. A classic study.
2. Nurden AT, George JN. Inherited abnormalities of the platelet membrane: Glanzmann thrombasthenia, Bernard-Soulier syndrome, and other disorders. In: Hemostasis and Thrombosis (5th Edition). Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber S (Eds). Lippincott, Williams & Wilkins, PA, USA, 987-1010 (2006).
3. Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: A review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 118(23), 5996-6005 (2011).
4. Patel D, Väänänen H, Jirousková M, Hoffmann T, Bodian C, Coller BS. Dynamics of GPIIb/IIIa-mediated platelet-platelet interactions in platelet adhesion/thrombus formation on collagen in vitro as revealed by videomicroscopy. Blood 101(3), 929-936 (2003).
5. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin αIIbß3) odyssey: A technologydriven saga of a receptor with twists, turns, and even a bend. Blood 112(8), 3011-3025 (2008).
6. Xiao T, Takagi J, Coller BS, Wang JH, Springer TA. Structural basis for allostery in integrins and binding to fibrinogenmimetic therapeutics. Nature 432(7013), 59-67 (2004).
7. Bolton-Maggs PH, Chalmers EA, Collins PW et al.; UKHCDO. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br. J. Haematol. 135(5), 603-633 (2006).
8. Siddiq S, Clark A, Mumford A. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia 17(5), e858-e869 (2011).
9. Seligsohn U. Treatment of inherited platelet disorders. Haemophilia 18(Suppl. 4), 1-5 (2012).
10. Morgan EA, Schneider JG, Baroni TE et al. Dissection of platelet and myeloid cell defects by conditional targeting of the β3-integrin subunit. FASEB J. 24(4), 1117-1127 (2010).
11. Kannan M, Ahmad F, Yadav BK, Kumar R, Choudhry VP, Saxena R. Molecular defects in ITGA2B and ITGB3 genes in patients with Glanzmann thrombasthenia. J. Thromb. Haemost. 7(11), 1878-1885 (2009).
12. Wilhide CC, Jin Y, Guo Q et al. The human integrin β3 gene is 63 kb and contains a 5́-UTR sequence regulating expression. Blood 90(10), 3951-3961 (1997).
13. Heidenreich R, Eisman R, Surrey S et al. Organization of the gene for platelet glycoprotein IIb. Biochemistry 29(5), 1232-1244 (1990).
14. Kunicki TJ, Williams SA, Nugent DJ, Yeager M. Mean platelet volume and integrin alleles correlate with levels of integrins α(IIb)β(3) and α(2)β(1) in acute coronary syndrome patients and normal subjects. Arterioscler. Thromb. Vasc. Biol. 32(1), 147-152 (2012).
15. Nurden P, Poujol C, Durrieu-Jais C et al. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport. Blood 93(5), 1622-1633 (1999).
16. Burk CD, Newman PJ, Lyman S, Gill J, Coller BS, Poncz M. A deletion in the gene for glycoprotein IIb associated with Glanzmann's thrombasthenia. J. Clin. Invest. 87(1), 270-276 (1991).
17. Jayo A, Pabón D, Lastres P, Jiménez-Yuste V, González-Manchón C. Type II Glanzmann thrombasthenia in a compound heterozygote for the αIIb gene. A novel missense mutation in exon 27. Haematologica 91(10), 1352-1359 (2006).
18. Emambokus NR, Frampton J. The glycoprotein IIb molecule is expressed on early murine hematopoietic progenitors and regulates their numbers in sites of hematopoiesis. Immunity 19(1), 33-45 (2003).
19. Mitchell WB, Li J, French DL, Coller BS. αIIbß3 biogenesis is controlled by engagement of αIIb in the calnexin cycle via the N15-linked glycan. Blood 107(7), 2713-2719 (2006).
20. Rosenberg N, Yatuv R, Sobolev V, Peretz H, Zivelin A, Seligsohn U. Major mutations in calf-1 and calf-2 domains of glycoprotein IIb in patients with Glanzmann thrombasthenia enable GPIIb/IIIa complex formation, but impair its transport from the endoplasmic reticulum to the Golgi apparatus. Blood 101(12), 4808-4815 (2003).
21. González-Manchón C, Arias-Salgado EG, Butta N et al. A novel homozygous splice junction mutation in GPIIb associated with alternative splicing, nonsense-mediated decay of GPIIb-mRNA, and type II Glanzmann's thrombasthenia. J. Thromb. Haemost. 1(5), 1071-1078 (2003).
22. Mansour W, Einav Y, Hauschner H, Koren A, Seligsohn U, Rosenberg N. An 〈IIb mutation in patients with Glanzmann thrombasthenia located in the N-terminus of blade 1 of the β-propeller (Asn2Asp) disrupts a calcium binding site in blade 6. J. Thromb. Haemost. 9(1), 192-200 (2011).
23. Nelson EJ, Li J, Mitchell WB, Chandy M, Srivastava A, Coller BS. Three novel β-propeller mutations causing Glanzmann thrombasthenia result in production of normally stable pro-αIIb, but variably impaired progression of pro-αIIbß3 from endoplasmic reticulum to Golgi. J. Thromb. Haemost. 3(12), 2773-2783 (2005).
24. Newman PJ, Seligsohn U, Lyman S, Coller BS. The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc. Natl Acad. Sci. USA 88(8), 3160-3164 (1991).
25. Rosenberg N, Yatuv R, Orion Y et al. Glanzmann thrombasthenia caused by an 11.2-kb deletion in the glycoprotein IIIα (β3) is a second mutation in Iraqi Jews that stemmed from a distinct founder. Blood 89(10), 3654-3662 (1997).
26. Rosenberg N, Hauschner H, Peretz H et al. A 13-bp deletion in α(IIb) gene is a founder mutation that predominates in Palestinian-Arab patients with Glanzmann thrombasthenia. J. Thromb. Haemost. 3(12), 2764-2772 (2005).
27. Schlegel N, Gayet O, Morel-Kopp MC et al. The molecular genetic basis of Glanzmann's thrombasthenia in a gypsy population in France: identification of a new mutation on the αIIb gene. Blood 86(3), 977-982 (1995).
28. Fiore M, Pillois X, Nurden P, Nurden AT, Austerlitz F. Founder effect and estimation of the age of the French Gypsy mutation associated with Glanzmann thrombasthenia in Manouche families. Eur. J. Hum. Genet. 19(9), 981-987 (2011).
29. Jallu V, Dusseaux M, Panzer S et al. αIIbß3 Integrin: new allelic variants in Glanzmann thrombasthenia, effects on ITGA2B and ITGB3 mRNA splicing, expression, and structure-function. Hum. Mutat. 31(3), 237-246 (2010).
30. D'Andrea G, Colaizzo D, Vecchione G, Grandone E, Di Minno G, Margaglione M; GLAnzmann's Thrombasthenia Italian Team (GLATIT). Glanzmann's thrombasthenia: identification of 19 new mutations in 30 patients. Thromb. Haemost. 87(6), 1034-1042 (2002).
31. Peretz H, Rosenberg N, Landau M et al. Molecular diversity of Glanzmann thrombasthenia in southern India: new insights into mRNA splicing and structure-function correlations of αIIbß3 integrin (ITGA2B, ITGB3). Hum. Mutat. 27(4), 359-369 (2006).
32. Toogeh G, Sharifian R, Lak M, Safaee R, Artoni A, Peyvandi F. Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am. J. Hematol. 77(2), 198-199 (2004).
33. Ruan C, Gu J, Wang X, Chu X, Pan J. Application of GPIIIa gene Taq I polymorphism to determination of carrier status in Glanzmann's thrombasthenia families of Chinese origin. Thromb. Haemost. 69(1), 64-69 (1993).
34. Sassetti B, Lajmanovich A, Vázquez A et al. Glanzmann thrombasthenia in children from Argentina. J. Pediatr. Hematol. Oncol. 18(1), 23-28 (1996).
35. Dokekias AE, Bopaka R, Malanda F, Schved JF. [Panorama of congenital disorders of hemostasis diseases at University Hospital of Brazzaville, Congo]. Med. Trop. (Mars.) 69(1), 102-103 (2009).
36. Rodeghiero F, Tosetto A, Abshire T et al.; ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC bleeding assessment tool: A standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J. Thromb. Haemost. 8(9), 2063-2065 (2010).
37. Chediak J, Telfer MC, Vander Laan B, Maxey B, Cohen I. Cycles of agglutination-disagglutination induced by ristocetin in thrombasthenic platelets. Br. J. Haematol. 43(1), 113-126 (1979).
38. Ruan J, Schmugge M, Clemetson KJ et al. Homozygous Cys542→Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann's thrombasthenia. Br. J. Haematol. 105(2), 523-531 (1999).
39. Ruiz C, Liu CY, Sun QH et al. A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (αIIbß3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenialike phenotype. Blood 98(8), 2432-2441 (2001).
40. Nurden AT, Ruan J, Pasquet JM et al. A novel 196Leu to Pro substitution in the β3 subunit of the αIIbß3 integrin in a patient with a variant form of Glanzmann thrombasthenia. Platelets 13(2), 101-111 (2002).
41. Peyruchaud O, Nurden AT, Milet S et al. R to Q amino acid substitution in the GFFKR sequence of the cytoplasmic domain of the integrin IIb subunit in a patient with a Glanzmann's thrombasthenia-like syndrome. Blood 92(11), 4178-4187 (1998).
42. Fiore M, Nurden AT, Vinciguerra C, Nurden P, Pillois X. Rapid diagnosis of the French gypsy mutation in Glanzmann thrombasthenia using high-resolution melting analysis. Thromb. Haemost. 104(5), 1076-1077 (2010).
43. Nurden AT, Pillois X, Fiore M, Heilig R, Nurden P. Glanzmann thrombasthenia-like syndromes associated with macrothrombocytopenias and mutations in the genes encoding the αIIbß3 integrin. Semin. Thromb. Hemost. 37(6), 698-706 (2011).
44. Coller BS, Cheresh DA, Asch E, Seligsohn U. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood 77(1), 75-83 (1991).
45. Morel-Kopp MC, Melchior C, Chen P et al. A naturally occurring point mutation in the β3 integrin MIDAS-like domain affects differently αvβ3 and αIIIbß3 receptor function. Thromb. Haemost. 86(6), 1425-1434 (2001).
46. Honda S, Kashiwagi H, Kiyoi T et al. Amino acid mutagenesis within ligand-binding loops in αv confers loss-of-function or gain-of-function phenotype on integrin αvβ3. Thromb. Haemost. 92(5), 1092-1098 (2004).
47. Chen P, Melchior C, Brons NH, Schlegel N, Caen J, Kieffer N. Probing conformational changes in the I-like domain and the cysteine-rich repeat of human β3 integrins following disulfide bond disruption by cysteine mutations: identification of cysteine 598 involved in αIIbß3 activation. J. Biol. Chem. 276(42), 38628-38635 (2001).
48. Ward CM, Kestin AS, Newman PJ A Leu262Pro mutation in the integrin β(3) subunit results in an α(IIb)-β(3) complex that binds fibrin but not fibrinogen. Blood 96(1), 161-169 (2000).
49. Chen YP, Djaffar I, Pidard D et al. Ser-752→Pro mutation in the cytoplasmic domain of integrin β3 subunit and defective activation of platelet integrin αIIb β3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia. Proc. Natl Acad. Sci. USA 89(21), 10169-10173 (1992).
50. Westrup D, Santoso S, Follert-Hagendorff K et al. Glanzmann thrombasthenia Frankfurt I is associated with a point mutation Thr176Ile in the N-terminal region of αIIb subunit integrin. Thromb. Haemost. 92(5), 1040-1051 (2004).
51. Lanza F, Stierlé A, Fournier D et al. A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg→214Trp mutation. J. Clin. Invest. 89(6), 1995-2004 (1992).
52. Loftus JC, O'Toole TE, Plow EF, Glass A, Frelinger AL 3rd, Ginsberg MH. A β3 integrin mutation abolishes ligand binding and alters divalent cationdependent conformation. Science 249(4971), 915-918 (1990).
53. Landau M, Rosenberg N. Molecular insight into human platelet antigens: structural and evolutionary conservation analyses offer new perspective to immunogenic disorders. Transfusion 51(3), 558-569 (2011).
54. Peterson JA, Pechauer SM, Gitter ML et al. New platelet glycoprotein polymorphisms causing maternal immunization and neonatal alloimmune thrombocytopenia. Transfusion 52(5), 1117-1124 (2012).
55. Moser M, Nieswandt B, Ussar S, Pozgajova M, Fässler R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat. Med. 14(3), 325-330 (2008).
56. Legrand C, Dubernard V, Nurden AT. Studies on the mechanism of expression of secreted fibrinogen on the surface of activated human platelets. Blood 73(5), 1226-1234 (1989).
57. Nurden P, Poujol C, Winckler J, Combrié R, Caen JP, Nurden AT. A Ser752→Pro substitution in the cytoplasmic domain of β3 in a Glanzmann thrombasthenia variant fails to prevent interactions between the αIIbß3 integrin and the platelet granule pool of fibrinogen. Br. J. Haematol. 118(4), 1143-1151 (2002).
58. Wang R, Shattil SJ, Ambruso DR, Newman PJ. Truncation of the cytoplasmic domain of β3 in a variant form of Glanzmann thrombasthenia abrogates signaling through the integrin α(IIb)β3 complex. J. Clin. Invest. 100(9), 2393-2403 (1997).
59. Kahner BN, Kato H, Banno A, Ginsberg MH, Shattil SJ, Ye F. Kindlins, integrin activation and the regulation of talin recruitment to αIIbß3. PLoS ONE 7(3), e34056 (2012).
60. Boylan B, Gao C, Rathore V, Gill JC, Newman DK, Newman PJ. Identification of FcgammaRIIa as the ITAM-bearing receptor mediating αIIbß3 outside-in integrin signaling in human platelets. Blood 112(7), 2780-2786 (2008).
61. Arias-Salgado EG, Butta N, González-Manchón C, Larrucea S, Ayuso MS, Parrilla R. Competition between normal [674C] and mutant [674R] subunits: role of the molecular chaperone BiP in the processing of GPIIb-IIIa complexes. Blood 97(9), 2640-2647 (2001).
62. Honda S, Tomiyama Y, Shiraga M et al. A two-amino acid insertion in the Cys146-Cys167 loop of the αIIb subunit is associated with a variant of Glanzmann thrombasthenia. Critical role of Asp163 in ligand binding. J. Clin. Invest. 102(6), 1183-1192 (1998).
63. Kiyoi T, Tomiyama Y, Honda S et al. A naturally occurring Tyr143His αIIb mutation abolishes αIIb β3 function for soluble ligands but retains its ability for mediating cell adhesion and clot retraction: comparison with other mutations causing ligand-binding defects. Blood 101(9), 3485-3491 (2003).
64. Milet-Marsal S, Breillat C, Peyruchaud O et al. Analysis of the amino acid requirement for a normal αIIbß3 maturation at αIIbGlu324 commonly mutated in Glanzmann thrombasthenia. Thromb. Haemost. 88(4), 655-662 (2002).
65. Kamata T, Ambo H, Puzon-McLaughlin W et al. Critical cysteine residues for regulation of integrin αIIbß3 are clustered in the epidermal growth factor domains of the β3 subunit. Biochem. J. 378(Pt 3), 1079-1082 (2004).
66. Mor-Cohen R, Rosenberg N, Einav Y et al. Unique disulfide bonds in epidermal growth factor (EGF) domains of β3 affect structure and function of αIIbß3 and αvβ3 integrins in different manner. J. Biol. Chem. 287(12), 8879-8891 (2012).
67. Mor-Cohen R, Rosenberg N, Peretz H et al. Disulfide bond disruption by a β 3-Cys549Arg mutation in six Jordanian families with Glanzmann thrombasthenia causes diminished production of constitutively active αIIb β3. Thromb. Haemost. 98(6), 1257-1265 (2007).
68. Milet-Marsal S, Breillat C, Peyruchaud O et al. Two different β3 cysteine substitutions alter αIIb β3 maturation and result in Glanzmann thrombasthenia. Thromb. Haemost. 88(1), 104-110 (2002).
69. Nurden A, Nurden P. Advances in our understanding of the molecular basis of disorders of platelet function. J. Thromb. Haemost. 9(Suppl. 1), 76-91 (2011).
70. Wilcox DA, Shi Q, Nurden P et al. Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. J. Thromb. Haemost. 1(12), 2477-2489 (2003).
71. González-Manchón C, Butta N, Larrucea S et al. A variant thrombasthenic phenotype associated with compound heterozygosity of integrin β3-subunit: (Met124Val)β3 alters the subunit dimerization rendering a decreased number of constitutive active αIIbß3 receptors. Thromb. Haemost. 92(6), 1377-1386 (2004).
72. Vanhoorelbeke K, De Meyer SF, Pareyn I et al. The novel S527F mutation in the integrin β3 chain induces a high affinity αIIbß3 receptor by hindering adoption of the bent conformation. J. Biol. Chem. 284(22), 14914-14920 (2009).
73. Hardisty R, Pidard D, Cox A et al. A defect of platelet aggregation associated with an abnormal distribution of glycoprotein IIb-IIIa complexes within the platelet: The cause of a lifelong bleeding disorder. Blood 80(3), 696-708 (1992).
74. Kunishima S, Kashiwagi H, Otsu M et al. Heterozygous ITGA2B R995W mutation inducing constitutive activation of the αIIbß3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia. Blood 117(20), 5479-5484 (2011).
75. Yang J, Ma YQ, Page RC, Misra S, Plow EF, Qin J. Structure of an integrin αIIbß3 transmembrane-cytoplasmic heterocomplex provides insight into integrin activation. Proc. Natl Acad. Sci. USA 106(42), 17729-17734 (2009).
76. Ghevaert C, Salsmann A, Watkins NA et al. A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the αIIbß3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia. Blood 111(7), 3407-3414 (2008).
77. Schaffner-Reckinger E, Salsmann A, Debili N et al. Overexpression of the partially activated α(IIb)β3D723H integrin salt bridge mutant downregulates RhoA activity and induces microtubuledependent proplatelet-like extensions in Chinese hamster ovary cells. J. Thromb. Haemost. 7(7), 1207-1217 (2009).
78. Gresele P, Falcinelli E, Giannini S et al. Dominant inheritance of a novel integrin β3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families. Haematologica 94(5), 663-669 (2009).
79. Jayo A, Conde I, Lastres P et al. L718P mutation in the membrane-proximal cytoplasmic tail of β3 promotes abnormal αIIb β3 clustering and lipid microdomain coalescence, and associates with a thrombasthenia-like phenotype. Haematologica 95(7), 1158-1166 (2010).
80. McDowall A, Inwald D, Leitinger B et al. A novel form of integrin dysfunction involving β1, β2, and β3 integrins. J. Clin. Invest. 111(1), 51-60 (2003).
81. Svensson L, Howarth K, McDowall A et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. Nat. Med. 15(3), 306-312 (2009).
82. Van de Vijver E, De Kuyper IM, Gerrits AJ et al. Defects in Glanzmann thrombasthenia and LAD-III (LAD-1/v) syndrome: The role of integrin β1 and β3 in platelet adhesion to collagen. Blood 119(2), 583-586 (2012).
83. Bialkowska K, Ma YQ, Bledzka K et al. The integrin co-activator kindlin-3 is expressed and functional in a non-hematopoietic cell, the endothelial cell. J. Biol. Chem. 285(24), 18640-18649 (2010).
84. D'Andrea G, Margaglione M; Glansmann's Thrombasthemia Italian Team (GLATIT). Glanzmann's thrombasthenia: modulation of clinical phenotype by α2C807T gene polymorphism. Haematologica 88(12), 1378-1382 (2003).
85. Duperat VG, Vergnes C, Nurden P, Nurden AT. Screening for factor V Leiden and a prothrombin gene polymorphism in patients with Glanzmann's thrombasthenia. Br. J. Haematol. 101(3), 593-594 (1998).
86. Ten Cate H, Brandjes DP, Smits PH, van Mourik JA. The role of platelets in venous thrombosis: A patient with Glanzmann's thrombasthenia and a factor V Leiden mutation suffering from deep venous thrombosis. J. Thromb. Haemost. 1(2), 394-395 (2003).
87. Rezende SM. Secondary prophylaxis with warfarin for recurrent thrombosis in a patient with Glanzmann thrombasthenia and F5 G1691A. Br. J. Haematol. 156(1), 144 (2012).
88. Phillips R, Richards M. Venous thrombosis in Glanzmann's thrombasthenia. Haemophilia 13(6), 758-759 (2007).
89. Hainaud P, Brouland JP, André P et al. Dissociation between fibrinogen and fibrin interaction with platelets in patients with different subtypes of Glanzmann's thrombasthenia: studies in an ex vivo perfusion chamber model. Br. J. Haematol. 119(4), 998-1004 (2002).
90. Brill A, Fuchs TA, Chauhan AK et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 117(4), 1400-1407 (2011).
91. Kannan M, Yadav BK, Ahmad F, Biswas A, Saxena R. Modulation of clinical phenotype of Glanzmann's thrombasthenia by thrombogenic mutations. Clin. Chim. Acta 403(1-2), 156-158 (2009).
92. Jacquelin B, Tuleja E, Kunicki TJ, Nurden P, Nurden AT. Analysis of platelet membrane glycoprotein polymorphisms in Glanzmann thrombasthenia showed the French gypsy mutation in the αIIb gene to be strongly linked to the HPA-1b polymorphism in β3. J. Thromb. Haemost. 1(3), 573-575 (2003).
93. Nurden AT, Breillat C, Jacquelin B et al. Triple heterozygosity in the integrin αIIb subunit in a patient with Glanzmann's thrombasthenia. J. Thromb. Haemost. 2(5), 813-819 (2004).
94. Gahl WA, Markello TC, Toro C et al. The National Institutes of Health Undiagnosed Diseases Program: insights into rare diseases. Genet. Med. 14(1), 51-59 (2012).
95. Albers CA, Paul DS, Schulze H et al. Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon-junction complex subunit RBM8A causes TAR syndrome. Nat. Genet. 44(4), 435-439, S1 (2012).
96. Poon MC, D'Oiron R, Von Depka M et al.; International Data Collection on Recombinant Factor VIIa and Congenital Platelet Disorders Study Group. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J. Thromb. Haemost. 2(7), 1096-1103 (2004).
97. Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired αIIb β3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 101(5), 1864-1870 (2003).
98. Lisman T, Adelmeijer J, Heijnen HF, de Groot PG. Recombinant factor VIIa restores aggregation of αIIbß3-deficient platelets via tissue factor-independent fibrin generation. Blood 103(5), 1720-1727 (2004).
99. Niewiarowski S, Levy-Toledano S, Caen JP. Platelet interaction with polymerizing fibrin in Glanzmann's thrombasthenia. Thromb. Res. 23(4-5), 457-463 (1981).
100. Nurden P, Youlouz-Marfak I, Siberchicot F et al. Use of autologous platelet-rich clots for the prevention of local injury bleeding in patients with severe inherited mucocutaneous bleeding disorders. Haemophilia 17(4), 620-624 (2011).
101. Nardone G, Rocco A, Balzano T, Budillon G. The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. Aliment. Pharmacol. Ther. 13(11), 1429-1436 (1999).
102. Coppola A, De Stefano V, Tufano A et al. Long-lasting intestinal bleeding in an old patient with multiple mucosal vascular abnormalities and Glanzmann's thrombasthenia: 3-year pharmacological management. J. Intern. Med. 252(3), 271-275 (2002).
103. Hauschner H, Landau M, Seligsohn U, Rosenberg N. A unique interaction between αIIb and β3 in the head region is essential for outside-in signaling-related functions of αIIbß3 integrin. Blood 115(22), 4542-4550 (2010).
104. Raborn J, Wang W, Luo BH. Regulation of integrin αIIbß3 ligand binding and signaling by the metal ion binding sites in the β I domain. Biochemistry 50(12), 2084-2091 (2011).
105. Jallu V, Diaz-Ricart M, Ordinas A, Pico M, Vezon G, Nurden AT. Two human antibodies reacting with different epitopes on integrin β3 of platelets and endothelial cells. Eur. J. Biochem. 222(3), 743-751 (1994).
106. Santoro C, Rago A, Biondo F et al. Prevalence of allo-immunization anti-HLA and anti-integrin αIIbß3 in Glanzmann thromboasthenia patients. Haemophilia 16(5), 805-812 (2010).
107. Léticée N, Kaplan C, Lémery D. Pregnancy in mother with Glanzmann's thrombasthenia and isoantibody against GPIIb-IIIa: is there a foetal risk? Eur. J. Obstet. Gynecol. Reprod. Biol. 121(2), 139-142 (2005).
108. Levy-Toledano S, Tobelem G, Legrand C et al. Acquired IgG antibody occurring in a thrombasthenic patient: its effect on human platelet function. Blood 51(6), 1065-1071 (1978).
109. Gruel Y, Brojer E, Nugent DJ, Kunicki TJ. Further characterization of the thrombasthenia-related idiotype OG. Antiidiotype defines a novel epitope(s) shared by fibrinogen B βchain, vitronectin, and von Willebrand factor and required for binding to β3. J. Exp. Med. 180(6), 2259-2267 (1994).
110. Fiore M, Firah N, Pillois X, Nurden P, Heilig R, Nurden AT. Natural history of platelet antibody formation against αIIbß3 in a French cohort of Glanzmann thrombasthenia patients. Haemophilia 18(3), e201-e209 (2012).
111. Srivastava A, Usher S, Nelson EJ et al. Prenatal diagnosis of Glanzmann thrombasthenia. Natl Med. J. India 16(4), 207-208 (2003).
112. Ruan J, Peyruchaud O, Nurden P et al. Family screening for a Glanzmann's thrombasthenia mutation using PCR-SSCP. Platelets 9(2), 129-136 (1998).
113. Bellucci S, Damaj G, Boval B et al. Bone marrow transplantation in severe Glanzmann's thrombasthenia with antiplatelet alloimmunization. Bone Marrow Transplant. 25(3), 327-330 (2000).
114. Flood VH, Johnson FL, Boshkov LK et al. Sustained engraftment post bone marrow transplant despite anti-platelet antibodies in Glanzmann thrombasthenia. Pediatr. Blood Cancer 45(7), 971-975 (2005).
115. Connor P, Khair K, Liesner R et al. Stem cell transplantation for children with Glanzmann thrombasthenia. Br. J. Haematol. 140(5), 568-571 (2008).
116. Wilcox DA, White GC 2nd. Gene therapy for platelet disorders: studies with Glanzmann's thrombasthenia. J. Thromb. Haemost. 1(11), 2300-2311 (2003).
117. Fang J, Jensen ES, Boudreaux MK et al. Platelet gene therapy improves hemostatic function for integrin αIIbß3-deficient dogs. Proc. Natl Acad. Sci. USA 108(23), 9583-9588 (2011).